Please login to the form below

Not currently logged in
Email:
Password:

John Brown joins board of BioCity Nottingham

Appointment follows expansion of BioCity's operations to Scotland

Dr John Brown, current chair of CXR Biosciences, has been appointed to the board of directors at BioCity Nottingham – one of Europe's largest life sciences research parks.

Dr Brown is also currently non-executive director of Vectura Group, chair of the Roslin Foundation in Scotland and co-chair of the Life Sciences Industry Advisory Board for the Scottish Government.

Other public sector work includes serving as non-executive director of the UK's Technology Strategy Board, a national agency to support innovation in business.

His appointment comes shortly after BioCity Nottingham announced plans to extend its operations, with the launch of BioCity Scotland in January, 2012, using a research facility formerly owned by Merck Sharp & Dohme.

Commenting on his appointment, Dr Brown said: “I'm delighted to be working with the BioCity team. Emulating the successful BioCity model at BioCity Scotland is just the first step for a company with exceptional growth potential.''

Previous positions held by Dr Brown in an extensive career in the life sciences industry include chair of both BTG and Axis-Shield, as well as spending five years at Glaxo Group Research.

He was also chief executive of UK-based vaccines biotech Acambis from 1997 until 2003.

Dr Louis Nisbet, chair of BioCity said: “Few individuals have the depth and breadth of experience that [Dr Brown] will bring to BioCity and to the companies we support.”

14th March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics